Attendee search 

Oxford BioMedica (LSE:OXB) is a leading gene therapy and immunotherapy company with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. The Company’s technology platforms include a highly efficient LentiVector® gene delivery system; a single administration to provide long-lasting therapy with specific advantages for targeting CNS and ocular diseases, and a unique tumour antigen (5T4) which is an ideal target for anti-cancer therapy.

The Company’s pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and its product candidates have the potential to transform treatment landscapes.  Oxford BioMedica’s capabilities cover the entire product lifecycle, from research to development to GMP manufacturing, with collaborative partners such as Sanofi, Pfizer, Novartis and some of the most prestigious clinical centres worldwide.  The Company recently secured significant funding via UK Government competitive awards such as the TSB regenerative medicine/cell therapy grant and AMSCI to build a centre of excellence for specialist manufacture of gene-based therapies.

Through in-house development programmes and industry collaborations, Oxford BioMedica’s goal is to improve the lives of patients with debilitating and life-threatening diseases.  Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.

The products and services Cambridge Bioscience offers includes:
·         Ion Channel, GPCR & Kinase Profiling Services
·         Primary screening  & Secondary Drug Profiling Services
·         Cardiac Safety Assessment
·         Ion Channel & GPCR Cell Lines
·         Human Tissues, TMAs & Biofluids
·         Primary Cells & Cell Culture Technologies

To find out more, please meet us at the event or contact us using the details below
Cambridge Bioscience
Munro House
Trafalgar Way
Bar Hill
Cambridge 
United Kingdom
CB23 8SQ

Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Email: support@bioscience.co.uk
Website: www.bioscience.co.uk

UKTI London's private sector International Trade Advisers support London based companies to develop their business internationally. This is achieved via provision of advice, training and delivery of UKTI services.

Supported by the Mayor's Export Program UKTI London is bringing a trade mission to  Bio-Europe. Kit Malthouse the Deputy Mayor of London for Business and Enterprise will be meeting the mission delegates at a networking breakfast on Tuesday Nov 5th.

Quay Pharma is one of the world’s leading Contract Development and Manufacturing Organisations, or CDMOs. Based in the UK, we provide specialist services to the pharmaceutical and biotech industries built on our unique expertise in drug formulation development, analytical services and contract manufacturing.

Quay provides formulation, analytical development and clinical trials manufacturing for companies world-wide. Applying strong project management, products are quickly and cost effectively taken from pre-clinical through phase II trials. Having deep knowledge in solid dosage form development, particularly improving bioavailability of NCEs, has resulted in many clients successfully licensing products on to large pharmaceutical companies.

Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity. 

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS.  Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing.  In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.

Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity. 

To find out more, please meet us at the event or contact us using the details below

Canbex Therapeutics Ltd

London BioScience Innovation Centre

2 Royal College Street

London

NW1 0NH

Tel: +44 (0)207 554 5872

Email: enquiries@canbex.co.uk

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Synpromics is a life science company focused on synthetic biology. Our core proprietary technology enables the design of optimized Synthetic Promoters to more effectively and efficiently regulate gene expression throughout biotechnology applications. Via product-development and distribution partnerships, Synpromics will commercially apply our novel promoters to enhance and expedite life science R&D, improve biology-based production processes, advance agricultural biotech and progress personalized medicine.

Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.

Selcia drug discovery provides integrated drug discovery services to support academics, institutions, biotech and pharma companies. Selcia assist in grant applications; execute the medicinal chemistry to deliver the best drug candidates, provide supporting project management and primary pharmacology, to ensure project success.

Selcia radiolabelling specialises in 14C GMP radiolabelling and produces 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, microdosing, research and regulatory studies; and environmental fate studies.

The purity and structure of our products are assured by our internal MHRA GLP accredited analytical department with 500MHz, 400MHz & 300MHz NMRs, mass spec and separation specialists. The group are experts in problem resolution to ensure projects meet agreed milestones.

Areas of Expertise:

• Medicinal chemistry:  Small molecules, macrocycles, natural product chemistry
• Disease expertise: Anti-infectives, inflammation, CNS, pain, metabolic
• Target classes: GPCRs, ion channels, enzymes, isomerases
• 14C Custom Radiosynthesis
• GMP Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds

www.selcia.com                               contact@selcia.com

Crescendo has developed a unique transgenic mouse which generates fully human VH single domain antibody fragments in the absence of contaminating murine light chains.

VH are the smallest, most robust antibody fragments with advantages for engineering of bispecific and multivalent products, tissue and tumour penetration, topical delivery and simple manufacture.  

Crescendo is applying the platform to a pipeline focused on inflammation and oncology, and topical delivery.

Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity. 

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS.  Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing.  In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.

Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity. 

To find out more, please meet us at the event or contact us using the details below

Canbex Therapeutics Ltd

London BioScience Innovation Centre

2 Royal College Street

London

NW1 0NH

Tel: +44 (0)207 554 5872

Email: enquiries@canbex.co.uk